CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Candel Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$8.21+0.02 (+0.24%)

Close on Oct 19, 2026

Market cap: $608.62M
P/E (TTM): –
Dividend yield: –

Candel Therapeutics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31
Depreciation & Amortization	–	–	–	–	–	–	–	–	–	–	–	–	0.81	0.81	0.78	0.74	0.57	0.37	0.23	0.06	0.08	0.10	0.09
Stock-Based Compensation	6.76	4.96	3.82	3.77	3.79	4.58	5.31	5.01	4.51	3.40	3.09	2.79	2.84	2.55	2.31	1.23	2.39	3.02	2.96	5.16	3.34	2.57	2.11
Change in Accounts Payable	3.37	1.99	0.80	0.71	1.32	0.27	-0.19	0.04	-0.03	-0.05	0.05	-0.67	-0.97	-0.49	-1.21	0.00	0.69	-0.08	0.67	-0.53	0.10	–	0.29
Change in Unearned Revenue	–	–	–	–	–	–	–	-0.16	-0.17	-0.18	-0.19	0.13	0.11	0.09	0.07	-0.13	-0.13	-0.13	-0.13	-0.13	-0.13	–	-0.13
Operating Cash Flow	-56	-48	-38	-34	-30	-27	-27	-29	-31	-32	-34	-34	-34	-34	-31	-30	-27	-25	-22	-20	-15	–	-9.07
Capital Expenditures	-1.30	-1.26	-0.59	-0.18	-0.04	-0.01	-0.02	-0.06	-0.16	-0.33	-0.46	-0.69	-0.80	-1.26	-1.30	-1.53	-1.70	-1.78	-1.84	-1.78	-2.12	–	-1.48
Sale of Property, Plant & Equipment	–	–	0.03	–	–	–	–	0.02	0.02	0.02	0.18	–	–	–	–	–	–	–	–	–	–	–	–
Investing Cash Flow	-1.27	-1.23	-0.56	-0.15	-0.04	-0.01	-0.02	-0.04	-0.14	-0.31	-0.28	-0.53	-0.64	-1.11	-1.30	-1.53	-1.70	-1.78	-1.84	19	19	–	38
Financing Cash Flow	158	152	56	104	109	94	94	2.25	0.57	-1.38	-0.12	0.04	0.04	0.06	20	20	91	92	72	72	0.47	–	0.49
Net Change in Cash	101	103	17	70	79	66	67	-26	-30	-34	-35	-45	-35	-35	-13	-0.13	62	65	48	70	3.98	–	30
Free Cash Flow	-57	-49	-39	-34	-30	-27	-27	-29	-31	-32	-35	-34	-35	-35	-33	-31	-29	-26	-24	-22	-17	–	-11
Income Taxes Paid	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.18	0.16	0.14	0.11	0.03	0.04	0.10	–	0.09
Interest Paid	3.28	2.25	1.28	0.90	1.20	1.50	1.80	2.02	2.15	2.20	2.15	1.90	1.86	1.54	1.15	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -64.6%

Financial strength

Current ratio: 16.09
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1589.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 4.83
Dividend yield: –